echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > First-line immunotherapy for bladder cancer! Mercadon Keytruda (Corrida) Joint Standard Care Chemotherapy First Line Treatment Phase III Clinical Failure!

    First-line immunotherapy for bladder cancer! Mercadon Keytruda (Corrida) Joint Standard Care Chemotherapy First Line Treatment Phase III Clinical Failure!

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    , June 10, 2020 /
    BiovalleyS/Merck and Corecently announced the results of the Third Under-361 Study (NCT02853305)The study is evaluating anti-PD-1 therapy Keytruda (Corrida, generic name: pembrolizumab, Paboli zumab) in combination with standard-based therapeutic chemotherapy (cisplatin or carped, joint gisitabin) for first-line treatment for patients with advanced or metastatic urinary skin cancer (bladder cancer)The results showed that Keytruda-chemotherapy did not reach the two main endpoints of pre-specified total survival (OS) and progression-free survival (PFS) compared to chemotherapyin the final analysis of the study, the Keytruda plus chemotherapy group improved in OS and PFS compared to the chemotherapy group; Since the Keytruda plus chemotherapy group had no advantage in OS or PFS, no formal test was conducted for the Study's Keytruda monodrug treatment groupKeytruda's safety in the study was consistent with previously reported studies, and no new safety signals were foundthe findings will be published at the upcomingand will be discussed with regulators"In this study, Keytruda combined chemotherapy conducted rigorous tests on patients with previously untreated advanced or metastatic bladder cancer, against the current standard combination of nursing chemotherapy," said DrRoy Baynes, Chief Medical Officer, Senior Vice President and Global Clinical Development Director,Mercado Research LaboratoryWhile we are disappointed with these findings, Keytruda has been identified as an important option for the treatment of metastatic bladder cancer and we are committed to continuing our research to help more patients with this diseaseWe thank the patients and researchers involved in this study"
    in the United States, Keytruda has been approved by the FDA for three bladder cancer indications, covering a variety of types and stages of bladder cancer, including: (1) for the treatment of patients with locally advanced or metastatic urinary tract skin cancer (mUC), including tumor expression PD-L1 (CPS-10) and not suitable for cisplatin chemotherapy, and not suitable for any patients with platinum chemotherapy, regardless of PD-L1 status; Patients with local late or metastatic (mUC) who progressed during or after receiving platinum-containing chemotherapy, or who developed disease progression within 12 months of new auxiliary or complementary treatment with platinum-containing chemotherapy; (3) patients with non-responsive, high risk, companion ship cancer (CIS), companionship or non-muscle-soaked bladder cancer (NMIBC) patients who do not fit or choose to accept bladder removalin addition, Mercado has extensive clinical development plans for bladder cancer and is continuing to evaluate Keytruda as a monotherapy, in conjunction with other cancer therapies,in a variety of disease sydments, such as metastatic, muscle-immersed bladder cancer, and non-muscle-immersed bladder cancerbladder cancer begins with bladder cells starting to grow uncontrollably, and as more cancer cells form, they form tumors and spread to other parts of the bodyUrinary skin cancer (UC) begins in the urine path cells inside the bladder and is the most common type of bladder cancer, accounting for about 90% of all bladder cancer casesIt is estimated that more than 549,000 new cases of bladder cancer and nearly 200,000 deaths worldwide will occur in 2018The 5-year survival rate of advanced or metastatic bladder cancer (phase IV) is only 5%Keytruda is a PD-(L) 1 tumor immunotherapy that helps detect and fight tumor cells by boosting the body's immune systemKeytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, activating T lymphocytes that may affecttumorcells and healthy cellsSo far, 11 PD-(L) 1oncologyimmunotherapy have been approved worldwide, of which Keytruda is the leader in the field, with more than 20 therapeutic indications approved and global sales reaching $11.1 billion in 2019, up 58% from the previous yearMercado has the largest clinical development of immunothologists in the industry, with more than 1,200clinical trials
    investigating Keytruda's role in a variety of types oftumorand therapeutic context The Keytruda Clinical Project aims to understand the drug's role in cancer and factors that may predict patients' benefits from Keytruda treatment, including exploring several different biomarker ( original source: Merck Provides Update Phase on 3 KEYNOTE-361 Trial Evaluating KEYTRUda ® (pembrolizumab) as Monotherapy and in R Groupy in Patients with Advanced or Meta Meta Urolia Carlioma
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.